Clinical Trials Logo

Clinical Trial Summary

This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma. Biological therapies, such as sargramostim, may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether sargramostim is more effective than hypertonic saline in treating patients with stage IB-II melanoma undergoing sentinel lymph node biopsy.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine if the alterations in morphology and phenotype to the sentinel lymph nodes are reversible.

II. To determine if the restoration of the morphology or phenotype of sentinel lymph nodes results in diminished regional tumor burden.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sargramostim subcutaneously (SC) 3-5 days prior to undergoing sentinel lymph node biopsy.

ARM II: Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.

After completion of study treatment, patients are followed up for 30 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01826864
Study type Interventional
Source Jonsson Comprehensive Cancer Center
Contact
Status Withdrawn
Phase Phase 3
Start date August 5, 2011
Completion date August 8, 2017

See also
  Status Clinical Trial Phase
Completed NCT01748747 - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Early Phase 1
Completed NCT00085189 - Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Phase 2
Active, not recruiting NCT01898403 - Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma N/A
Completed NCT00089063 - Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma Phase 2
Completed NCT00669019 - Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Phase 2
Completed NCT00003895 - Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma Phase 2